# Ardent Health earnings guidance and results

> Live situation record from CLSTR: https://clstr.news/situations/ardent-health-earnings-guidance-and-results
> Updated: 2026-08-04T20:41:35.000Z. Sources: 2. Developments: 2.

On 3 August 2026, Ardent Health (NYSE: ARDT) issued its fiscal‑year‑2026 outlook, forecasting earnings per share of $0.78‑$1.15 and revenue of $6.4‑$6.7 billion, both below analyst consensus. The company’s shares were trading near $10.74.

The following day, 4 August 2026, the firm reported its quarterly results, posting EPS of $0.12, which missed the $0.18 consensus estimate, and revenue of $1.62 billion, slightly above expectations. Net margin was 2.09% and return on equity 13.85%. Ardent reaffirmed its FY 2026 EPS guidance range of $0.78‑$1.15, and the stock remained around $10.74. Institutional investors, including First Trust Advisors and several banks, increased their holdings during the quarter.

## Timeline

### 2026-08-04: Arcutis Biotherapeutics insider sale and Arista Networks receives $3.6M investment

Arcutis Biotherapeutics posted strong earnings and insiders sold shares, while Arista Networks attracted a $3.6 M investment from Mirador Capital and saw insider sales by Andreas Bechtolsheim.

2 sources. https://clstr.news/cluster/ardent-health-reports-earnings-miss-and-sees-institutional-buying

### 2026-08-03: Ardent Health Issues FY 2026 Guidance; Aptiv Reports Q2 Results

Ardent Health set FY‑2026 EPS at $0.78‑$1.15 and revenue $6.4‑$6.7 B, below forecasts; Aptiv posted Q2 revenue $3.3 B, EPS $1.63, citing weak China demand and growth in non‑automotive segments.

2 sources. https://clstr.news/cluster/ardent-health-issues-fy-2026-guidance-aptiv-reports-q2-results

---
Cite as: Ardent Health earnings guidance and results. CLSTR, https://clstr.news/situations/ardent-health-earnings-guidance-and-results